原著論文

2022

1. Mochizuki L, Sano H, Honkura N, Masumoto K, Urano T, Suzuki Y. Visualization of Domain- and Concentration-Dependent Impact of Thrombomodulin on Differential Regulation of Coagulation and Fibrinolysis. Online ahead of print.
   
2. Urano T, Yasumoto A, Yokoyama K, Horiuchi H, Morishita E, Suzuki Y. COVID-19 and Thrombosis: Clinical Aspects. Curr Drug Targets. Online ahead of print.
3. Kugo H, Enomoto H, Yanagimoto K, Tanaka H, Moriyama T, Zaima N Eicosapentaenoic acid is associated with the attenuation of dysfunctions of mesenchymal stem cells in the abdominal aortic aneurysm wall. Food Funct. 13:7540-7547. 2022
4. Tanaka A, Inami W, Suzuki Y, Kawata Y. Development of a direct point electron beam exposure system to investigate the biological functions of subcellular domains in a living biological cell.
   Micron. Apr;155:103214. 2022
5. Kugo H, Tanaka H, Moriyama T, Zaima N. Characteristic distribution of eicosapentaenoic acid in human abdominal aortic aneurysm wall. J Lipid Res. Mar 18:100200. 2022
6. Ito T, Suzuki Y, Sano H, Honkura N, Castellino FJ, Urano T. Demonstration of Three Distinct High-Molecular-Weight Complexes between Plasminogen Activator Inhibitor Type 1 and Tissue-Type Plasminogen Activator. Thromb Haemost. Mar;122(3):336-343. 2022
7. Mathews NS, Suzuki Y, Honkura N, Sano H, Iwashita T, Urano T. Pre-administration of a carboxypeptidase inhibitor enhances tPA-induced thrombolysis in mouse microthrombi: Evidence from intravital imaging analysis. Thromb Res. Feb;210:78-86. 2022
8. Wendelboe AM, Langenfeld H, Ageno W, Castellucci L, Cesarman-Maus G, Ddungu H, De Paula EV, Dumantepe M, Forgo G, Guillermo Esposito MC, McLintock C, Ní Áinle F, Spyropoulos AC, Urano T, Barco S, Hunt BJ. Current practices of standardized risk assessment for venous thromboembolism: Results from a global survey from the World Thrombosis Day steering committee. J Thromb Haemost. Feb;20(2):532-535. 2022
9. Forgo G, Micieli E, Ageno W, Castellucci LA, Cesarman-Maus G, Ddungu H, De Paula EV, Dumantepe M, Guillermo Esposito MC, Konstantinides SV, Kucher N, McLintock C, Ní Áinle F, Spyropoulos AC, Urano T, Hunt BJ, Barco S. An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta-analysis. J Thromb Haemost. Feb;20(2):409-421. 2022

2021

1. Takeda R, Islam A, Sato T, Kurita H, Kahyo T, Urano T, Setou M. The stability of the metabolic turnover of arachidonic acid in human unruptured intracranial aneurysmal walls is sustained.
   Clin Neurol Neurosurg. Sep;208:106881. 2021
2. Tanaka H, Xu B, Xuan H, Ge Y, Wang Y, Li Y, Wang W, Guo J, Zhao S, Glover KJ, Zheng X, Liu S, Inuzuka K, Fujimura N, Furusho Y, Ikezoe T, Shoji T, Wang L, Fu W, Huang J, Unno N, Dalman RL. Recombinant Interleukin-19 Suppresses the Formation and Progression of Experimental Abdominal Aortic Aneurysms. J Am Heart Assoc. Sep 7;10(17):e022207. 2021
3. Barco S, Valerio L, Gallo A, Turatti G, Mahmoudpour SH, Ageno W, Castellucci LA, Cesarman-Maus G, Ddungu H, De Paula EV, Dumantepe M, Goldhaber SZ, Guillermo Esposito MC, Klok FA, Kucher N, McLintock C, Ní Áinle F, Simioni P, Spirk D, Spyropoulos AC, Urano T, Zhai ZG, Hunt BJ, Konstantinides SV. Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. Res Pract Thromb Haemost. Jun 15;5(5):e12520. 2021
4. Horiuchi H, Morishita E, Urano T, Yokoyama K; Questionnaire-survey Joint Team on The COVID-19-related thrombosis. COVID-19-Related Thrombosis in Japan: Final Report of a Questionnaire-Based Survey in 2020. J Atheroscler Thromb. Apr 1;28(4):406-416, 2021

2020

1. Suzuki Y, Tanaka H, Horinouchi T, Sano H, Honkura N, Unno N, Miwa S, Urano T. Fibrinolysis-resistant carbonylated fibrin detected in thrombi attached to the vascular wall of abdominal aortic aneurysms. Sci Rep. Nov 26;10(1):20728, 2020
2. Suzuki Y, Sano H, Mochizuki L, Honkura N, Urano T. Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system. Blood Adv. Nov 10;4(21):5501-5511, 2020
3. Thachil J, Longstaff C, Favaloro EJ, Lippi G, Urano T, Kim PY; SSC Subcommittee on Fibrinolysis of the International Society on Thrombosis and Haemostasis. The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on fibrinolysis. J Thromb Haemost. Sep;18(9):2408-2411, 2020
4. Sano M, Hirakawa S, Suzuki M, Sakabe JI, Ogawa M, Yamamoto S, Hiraide T, Sasaki T, Yamamoto N, Inuzuka K, Tanaka H, Saito T, Sugisawa R, Katahashi K, Yata T, Kayama T, Urano T, Tokura Y, Sato K, Setou M, Takeuchi H, Konno H, Unno N. Potential role of transforming growth factor-beta 1/Smad signaling in secondary lymphedema after cancer surgery. Cancer Sci. Jul;111(7):2620-2634, 2020
5. Moore HB, Gando S, Iba T, Kim PY, Yeh CH, Brohi K, Hunt BJ, Levy JH, Draxler DF, Stanworth S, Görlinger K, Neal MD, Schreiber MA, Barrett CD, Medcalf RL, Moore EE, Mutch NJ, Thachil J, Urano T, Thomas S, Scărlătescu E, Walsh M; Subcommittees on Fibrinolysis, Disseminated Intravascular Coagulation, and Perioperative and Critical Care Thrombosis and Hemostasis. Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. J Thromb Haemost. Mar;18(3):740-747, 2020
6. Tanaka H, Zaima N, Kugo H, Yata T, Iida Y, Hashimoto K, Miyamoto C, Sasaki T, Sano H, Suzuki Y, Moriyama T, Shimizu H, Inuzuka K, Urano T, Unno N. The Role of Animal Models in Elucidating the Etiology and Pathology of Abdominal Aortic Aneurysms: Development of a Novel Rupture Mechanism Model. Ann Vasc Surg. Feb;63:382-390, 2020

2019

1. Urano T, Suzuki Y. Assessing plasminogen activation potential with global fibrinolytic assays. Res Pract Thromb Haemost. Dec 26;4(1):13-15, 2019
2. Hashimoto T, Mogami H, Tsuriya D, Morita H, Sasaki S, Kumada T, Suzuki Y, Urano T, Oki Y, Suda T. G-protein-coupled receptor 40 agonist GW9508 potentiates glucose-stimulated insulin secretion through activation of protein kinase Cα and ε in INS-1 cells. PLoS One. Sep 9;14(9):e0222179, 2019
3. Urano T, Suzuki Y, Iwaki T, Sano H, Honkura N, Castellino FJ. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis. Curr Drug Targets. ;20(16):1695-1701, 2019

2018

1. Tanaka H, Inuzuka K, Iida Y, Shimizu H, Unno N, Urano T. Proprotein Convertase Subtilisin/Kexin Type 9 Is Associated with Degenerating Adipocytes in Abdominal Aortic Aneurysm. J Oleo Sci. Oct 11;67(10):1355-1360, 2018
2. Sugiura K, Ojima T, Urano T, Kobayashi T. The incidence and prognosis of thromboembolism associated with oral contraceptives: Age-dependent difference in Japanese population. J Obstet Gynaecol Res. Sep;44(9):1766-1772, 2018
3. Urano T, Castellino FJ, Suzuki Y. Regulation of plasminogen activation on cell surfaces and fibrin. J Thromb Haemost. 16:1487-1497, 2018
4. Tanaka H, Unno N, Suzuki Y, Sano H, Yata T, Urano T. Hypoperfusion of the aortic wall secondary to degeneration of adventitial vasa vasorum causes abdominal aortic aneurysms. Curr Drug Targets Jan 22, 2018
5. Hashimoto K, Kugo H, Tanaka H, Miyamoto C, Uranon T, Unno N, Zaima N, Moriyama T. The effect of high fat diet on development of abdominal aortic aneurysm in vascular hypoperfusion-induced animal model. J Vasc Res 55(2):63-74, 2018
6. Tanaka H, Iida Y, Iwaki T, Suzuki Y, Sano H, Miyajima C, Zaima N, Sasaki T, Sumioka A, Hakamata S, Shimizu H, Umemura K, Urano T. Elevated Plasma Levels of LDL Cholesterol Promote Dissecting Thoracic Aortic Aneurysms in Angiotensin II-Induced Mice. Ann Vasc Surg 48:204-213, 2018
7. Iida Y, Tanaka H, Sano H, Suzuki Y, Shimizu H, Urano T. Ectopic Expression of PCSK9 by Smooth Muscle Cells Contributes to Aortic Dissection. Ann Vasc Surg 48:195-203, 2018

2017

1. Wendelboe AM, Raskob GE, Angchaisuksiri P, Blanco AN, Büller H, Ddungu H, Dvorak JD, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, McLintock C, Urano T, Weitz JI. Global public awareness about atrial fibrillation. Res Pract Thromb Haemost. Oct 25;2(1):49-57, 2017
2. Brzoska T, Suzuki Y, Sano H, Suzuki A, Tanaka H, Urano T. Imaging analyses of coagulation-dependent initiation of fibrinolysis on activated platelets and its modification by thrombin-activatable fibrinolysis inhibitor. Thromb Haemost 7. 682-690. doi.org/10.1160/TH16-09-0722, 2017
3. H Kugo, N Zaima, H Tanaka, T Urano, N Unno, T Moriyama The effects of nicotine administration on pathophysiology of rat vascular wall. Biotechnic & Histochemistry 92(2):141-148, 2017
4. Iwaki T, Nagahashi K, Takano K, Suzuki-Inoue K, Kanayama N, Umemura K, Urano T. Mutation in a highly conserved glycine residue in strand 5B of plasminogen activator inhibitor 1 causes polymerization. Thromb Haemost 117(5):860-869, 2017
5. Urano T, Suzuki Y. (editorial) Thrombolytic therapy targeting alpha 2-antiplasmin. Circulation. 135:1021-1023 DOI: 10.1161/CIRCULATIONAHA.117.026884, 2017
6. Kugo H, Zaima N, Tanaka H, Hashimoto K, Miyamoto C, Sawaragi A, Urano T, Unno N, Moriyama T. Pathological Analysis of the Ruptured Vascular Wall of Hypoperfusion-induced Abdominal Aortic Aneurysm Animal Model. J Oleo Sci 66(5), 499-506, 2017
7. Tanaka H, Zaima N, Sasaki T, Yamamoto N, Inuzuka K, Yata T, Iwaki T, Umemura K, Sano H, Suzuki Y, Urano T, Setou M, Unno N. Lysophosphatidylcholine Acyltransferase-3 Expression Is Associated with Atherosclerosis Progression. J Vasc Res 54(4), 200-208, 2017
8. Wendelboe, Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Ddungu, H, Dvorak JD, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, McLintock C, Urano T, Weitz J. Global Public Awareness about Atrial Fibrillation. Res Pract Thromb Haemost. ;1-9. 2017
9. Iida Y, Tanaka H, Urano T, Unno N, Shimizu H. PC194 Ectopic Expression of Proprotein Convertase Subtilisin Kexin Type 9 by Smooth Muscular Cells Contributes to Aortic Dissection. J Vasc Surg 65(6), 192S-193S, 2017
10. Takechi D, Kuroda N, Dote H, Kim E, Yonekawa O, Watanabe T, Urano T, Homma Y. Better documentation in electronic medical records would lead to an increased use of lower extremity venous ultrasound in the inpatient setting: a retrospective study. Acute Med Surg 4(4), 385-393, 2017
11. Tanaka H, Unno N, Yata T, Kugo H, Zaima N, Sasaki T, Urano T. Creation of a Rodent Model of Abdominal Aortic Aneurysm by Blocking Adventitial Vasa Vasorum Perfusion. J Vis Exp Nov 8;(129), 2017

2016

1. Suzuki Y, Sano H, Tomczyk M, Brzoska T, Urano T. Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells. FEBS Open Bio 6:469-76, 2016
2. Tanaka H, Yamamoto N, Suzuki M, Mano Y, Sano M, Zaima N, Sasaki T, Setou M, Unno N: Insufficient Lymph Drainage Causes Abnormal Lipid Accumulation and Vein Wall Degeneration. Ann Vasc Dis 9(4):277-284, 2016
3. Tomczyk M, Suzuki Y, Sano H, Brzoska T, Tanaka H, Urano T.　Bidirectional functions of thrombin on fibrinolysis: Evidence of thrombin-dependent enhancement of fibrinolysis provided by spontaneous plasma clot lysis. Thromb Res 143:28-33, 2016
4. Hosokawa K, Ohnishi-Wada T, Sameshima-Kaneko H, Nagasato T, Miura N, Kikuchi K, Koide T, Maruyama I, Urano T. Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in-vitro flow chamber model. Thromb Res 146:69-75, 2016
5. Kugo H, Zaima N, Tanaka H, Mouri Y, Yanagimoto K, Hayamizu K, Hashimoto K, Sasaki T, Sano M, Yata T, Urano T, Setou M, Unno N, Moriyama T. Adipocyte in vascular wall can induce the rupture of abdominal aortic aneurysm. Sci Rep 6:31268, 2016
6. Tanaka H, Zaima N, Sasaki T, Yamamoto N, Inuzuka K, Sano M, Konno H, Urano T, Setou M, Unno N. Characteristic Distribution Pattern of Lysophosphatidylcholine in Fibromuscular Dysplasia-Associated Visceral Artery Aneurysms Compared with Atherosclerotic Visceral Artery Aneurysms. J Atheroscler Thromb 23(6):673-80, 2016
7. Kugo H, Zaima N, Mouri Y, Tanaka H, Yanagimoto K, Urano T, Unno N, Moriyama T. The preventive effect of fish oil on abdominal aortic aneurysm development. Biosci Biotechnol Biochem 80(6):1186-91, 2016
8. Asai J, Hirakawa S, Sakabe J, Kishida T, Wada M, Nakamura N, Takenaka H, Mazda O, Urano T, Suzuki-Inoue K, Tokura Y, Katoh N. Platelets Regulate the Migration of Keratinocytes via Podoplanin/CLEC-2 Signaling during Cutaneous Wound Healing in Mice. Am J Pathol 186(1):101-8, 2016

2015

1. Brzoska T, Tanaka-Murakami A, Suzuki Y, Sano Hideto, Kanayama N, Urano T. Endogenously generated plasmin at the vascular wall injury site amplifies lysine binding site-dependent plasminogen accumulation in microthrombi. PloS One 10(3), e0122196, 2015　　

2013

1. Brzoska T, Suzuki Y, Mogami H, Sano H, Urano T. Binding of thrombin-activated platelets to a fibrin scaffold through α(IIb)β3 evokes phosphatidylserine exposure on their cell surface. PloS One 8(2), e55466, 2013
2. Yasui H, Suzuki Y, Sano H, Suda T, Chida K, Dan T, Miyata T, Urano T. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells. Thrmob Res 132(1),100-105, 2013

2012　

1. Iwaki T, Urano T, Umemura K. PAI-1 progress in understanding the clinical problem and its aetiology. Br J Haematol 157(3), 291-298, 2012
2. Nishimura S, Manabe I, Nagasaki M, Kakuta S, Iwakura Y, Takayama N, Ooehara J, Otsu M, Kamiya A, Petrich B, Urano T, Kadono T, Sato S, Aiba A, Yamashita H, Sugiura S, Kadowaki T, Nakauchi H, Eto K, and Nagai R. In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood 119(8), 45-56, 2012
3. Kramkowski K, Leszczynska A, Mogielnicki A, Chlopicki S, Fedorowicz A, Grochal E, Mann B, Brzoska T, Urano T, Motterlini R, Buczko W. Anti-thrombotic properties of water-soluble carbon monoxide-releasing molecules (CO-RMS). ATVB, 32(9), 2149-57, 2012

2011

1. Suzuki Y, Yasui H, Brzoska T, Mogami H, Urano T. Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells. Blood 118(11), 3182-3185, 2011
2. Ryobaltowski M, Suzuki Y, Mogami H, Chlebinska I, Brzoska T, Tanaka A, Bannno F, Miyata T, Urano T. In vivo imaging analysis of the interaction between unusually large von Willebrand factor multimers and platelets on the surface of vascular wall. Pflugers Arch 461(6), 623-633, 2011
3. Iwaki T, Tanaka A, Miyawaki Y, Suzuki A, Kobayashi T, Takamatsu J, Matsushita T, Umemura K, Urano T, Kojima T, Terao T,Kanayama N. Life-threatening hemorrhage and prolonged wound haeling are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 9(6), 1200-1206, 2011

2009

1. Hoki S, Suzuki Y, Umemura K, Urano T.Enhancement of fibrinolysis by gel-filtered platelets and its quenching by cytochalasin B and GPIIb/IIIa antagonists.Pharmacological Reports 61(5),877-84, 2009
2. Tanaka A, Suzuki Y, Sugihara K, Kanayama N, Urano T. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factorsin-vitro.Life Scineces 85(5/6), 220-225, 2009
3. Suzuki Y, Mogami H, Ihara Y, Urano T. Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. Blood 113, 470-478, 2009
4. Yashiro K, Matsumoto Y, Ihara H, Suzuki Y, Kondo K,Urano T,Umemura K. Involvement of platelet activation by P2Y12 receptor in the development of transplant arteriosclerosis in mice.Transplantation, 87(3), 660-667, 2009
5. Adachi E, Kazoe Y, Sato Y, Suzuki Y, Urano T, Ueyama T, Saito N, Nikolaev VO, LohseMJ,Tominaga M, Mogami H.A technique for monitoring multiple signals with a combination of prism-based total internal reflection fluorescence microscopy and epifluorescence microscopy Pflugers Arch - Eur J Physiol 459(1),227-34, 2009

2008

1. Hayashi T, Mogami H, Murakami Y, Nakamura T, Kanayama N, Konno K, UranoT. Real-time analysis of platelet aggregation and procoagulant activity during thrombus formation in vivo.Pflugers Archiv-European Journal of Physiology 456(6), 1239-51, 2008
2. Suwa D, Konno H, Tanaka T, Urano T. Intraperitoneal Infusion of Recombinant Plasminogen Activator inhibitor Type 2 Induced Apoptosis in Implanted Human Colon Cancer and Inhibited its Growth and Liver Metastasis.Anticancer Research 28(2A), 693-698, 2008

2006

1. Nakamura R, Umemura K, Hashimoto H, Urano T.Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin. Thromb Haemost 95, 637-42, 2006
2. Hryszko T, Inaba K, Ihara H, Suzuki Y, Mogami H, Urano T. Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1. The Journal of Trauma, Injury, Infection and Critical Care 60(4), 859-64, 2006
3. Suzuki Y, Zhang H, Saito N, Urano T, Kojima N, Mogami H.Glucagon-Like Peptide 1 Activates Protein Kinase C Through a Ca2+-Dependent Phospholipase C Activation in Insulin-Secreting Cells. J Biol Chem 281(39), 28499-28507, 2006

2005

1. Hryszko T, Suzuki Y, Mogami H, Urano T. Protein S attenuates the invasive potential of THP-1 cells by interfering with plasminogen binding on cell surface via a protein C-independent mechanism. FEBS Letters 579(27), 6023-6, 2005
2. Terada H, Urano T, Konno H.　Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer.Eur. Surg. Res. 37, 166-172, 2005
3. Inaba K, Suzuki S, Ihara H, Sakaguchi T, Baba S, Urano T, Konno H, Nakamura S. Sexual dimorphism in endotoxin susceptibility after partial hepatectomy in rats. J Hepatol 42(5), 719-27, 2005
4. Takahashi H, Nagai N and Urano T. Role of tissue plasminogen activator/plasmin cascade in delayed neuronal death after transient forebrain ischemia. Neuroscience Letters 381, 189-193, 2005
5. TakahashiT, SuzukiK, IharaH, MogamiH, KazuiT and UranoT. Plasminogen activator inhibitor-1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin viaavb5integrin. Semin Thromb Hemost. 31(3), 356-363, 2005

2004

1. Hryszko T, and Urano T. Activated Protein C enhances tPA-catalyzed Glu-plasminogen activation in the presence of poly-D-lysine.Thrombosis & Haemostasis 92(4), 891-2, 2004
2. Zhao BQ, Ikeda Y, Ihara H, Urano T, Fan WY, Mikawa S, Suzuki Y, Kondo K, Sato K, Nagai N and Umemura K. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 103(7), 2610-2616, 2004

2003

1. Urano T, Castellino FJ, Ihara H, Suzuki Y, Ohta M, Suzuki K, Mogami H. Activated protein C attenuates coagulation-associated over　expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1. Journal of Thrombosis and Hemostasis 1, 2615-2620, 2003
2. Suzuki Y, Kondo K, Matsumoto Y, Zhao BQ, Otsuguro K, Maeda T, Tsukamoto Y, Urano T, Umemura K. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery.Life Sci 73(10), 1289-98, 2003
3. Mogami H, Zhang H, Suzuki Y, Urano T, Saito N, Kojima I, and Petersen OH. Decoding of short-lived Ca2+influx signals into long-term substrate phosphorylation through activation of two distinct classes of protein kinase C. J Biol Chem 278(11), 9896-9904, 2003
4. Suzuki Y, Kondo K, Ichise H, Tsukamoto Y, Urano T and Umemura. K. Dietary supplementation with fermented soybeans suppresses intimal thickening. Nutrition. 19 (3), 261-264, 2003

2002

1. Sakata K, Pawlak R, Urano T and Takada A Effects of a longterm pharmacological interruption of the rennin-angiotensin system on the fibrinolytic system in essential hypertension. Pathophysiology of Haemostasis and Thrombosis. 32, 67-75, 2002
2. YoshidaM, NaitoY, UranoT, TakadaA and Takada Y. L-158,809 and (D-Ala7)-angiotensin I/II (1-7) decrease PAI-1 release from human umbilical vein endothelial cells. Thromb. Res. 105(6), 531-536, 2002
3. Takahashi H, Takada Y, Urano T and Takada A. 5-HT4 receptors in the hippocampus modulate rat locomotor activity. Hippocampus 12, 304-310, 2002
4. Nagai N, Zhao BQ, Suzuki Y, Ihara H, Urano T, Takada A, Umemura K.Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice. J Cereb Blood Flow Metab. 22, 648-651, 2002
5. Pawlak R-, NagaiN, UranoT, Napiorkowska-PawlakD, IharaH, TakadaY , Collen D.and TakadaA. Rapid, specific and active site-catalyzed effect of tissue-plasminogen activator on hippocampus-dependent learning in mice. Neuroscience 113(4), 995-1001, 2002
6. Yoshino A, Suzuki K, Urano T, Aoki K, Takada Y and Takada A Enhanced secretion of tissue plasminogen activator by simultaneous use of retinoic acid and ascorbic acid from tissue cultured gastroepiploic artery. Life Sciences70, 1461-1470, 2002

2001

1. Urano T., Ihara H., Umemura K., Suzuki Y., Oike M., Akita S., Tsukamoto Y., Suzuki I. and Takada A.　　The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1.J Biol Chem 276(27): 24690-24696, 2001
2. Konno H, Abe J, Kaneko T, Baba M, Shoji A, Sunayama K, Kamiya K, Tanaka T, Suzuki S, Nakamura S, Urano T. Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.Jpn J Cancer Res. 92(5): 516-523, 2001
3. Aoki K, Aikawa N, Sekine K, Yamazaki M, Mimura T, Urano T and Takada A. Elevation of plasma free PAI-1 levels as an integrated endothelial response to severe burs. Burns 27, 569-575, 2001
4. Ihara, H., Urano, T., Takada, A. and Loskutoff D. J. Induction of plasminogen activator inhibitor-1 (PAI-1) gene expression in adipocytes by thiazolidinediones. FASEB J.15(7):1233-1235, 2001
5. Urano T., Suzuki Y., Arakida M., Kanamori M. and Takada A. The expression of exercise-induced tPA activity in blood is regulated by the basal level of PAI-1. Thromb. Haemost. 85, 751-752, 2001
6. Pawlak R, Napiorkowska-Pawlak D, Takada Y, Urano T, Nagai N, Ihara H, Takada A. The differential effect of angiotensin II and angiotensin 1-7 on norepinephrine, epinephrine, and dopamine concentrations in rat hypothalamus: the involvement of angiotensin receptors. Brain Res Bull. 54(6): 689-694, 2001
7. Takahashi H, Takada Y, Urano T, Takada A. Dissociation of systemic and hippocampal modulation of rat locomotor activity by 5-HT(2C) receptors. Neurosci Res. 40(1): 97-103, 2001
8. Nagai N., YamamotoS., TsuboiT., IharaH., UranoT., TakadaY., TerakawaS. and TakadaA. Tissue-type plasminogen activator enhances neuronal death induced by oxygen-glucose-deprivation in culture. J Cereb Blood Flow Metab. 21(6): 631-634. 2001

～2000

1. Urano, T., Ihara, H., Takada, Y., Fujie, M. and Takada, A.The cleavage and inactivation of plasminogen activator inhibitor type 1 and a2-antiplasmin by reptilase, a thrombin-like venom enzyme.Blood Coagulation & Fibrinolysis 11(2), 145-153, 2000
2. Takahashi, H., Urano, T., Takada, Y., Nagai, N. and Takada, A. Neutrophil Elastase May Play a Key Role in the Development of Symptomatic DIC and Multiple Organ Failure in Patients with Head Injury. J. Trauma 49, 86-91, 2000
3. Urano, T., Ihara, H., Suzuki, Y., Takada, Y. and Takada. A. Coagulation Associated Enhancement of Fibrinolytic Activity Via a Neutralization of PAI-1 Activity. Semin. Thromb. Hemost. 26(1), 39-42, 2000
4. Ahaneku, J.E., Sakata, K., Urano, T., Takada, Y. and Takada, A. Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during treatment of hypertension with cilnidipine. Pharmaclogical Research 41(1), 81-84, 2000
5. Ahaneku, J.E., Sakata, K., Urano, T., Takada, Y. and Takada, A. Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during amlodipine treatment of hypertension in Japanese. Pharmaclogical Research 41(1), 75-79, 2000
6. Fujii, M., Hayakawa, H., Urano, T., Sato, A., Chida, K., Nakamura, H. and Takada, A. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb. Res. 99, 111-117, 2000
7. Urano, T., Ihara, H., Suzuki, Y., Nagai, N., Takada, Y. and Takada, A. Soluble thrombomodulin quenches thrombin-mediated neutralization of PAI-1 activity and inhibits fibrinolysis through a TAFI independent mechanism.Fibrinolysis & Proteolysis 13(6), 264-271, 1999
8. Abe, J., Urano, T., Konno, H., Erhan, Y., Tanaka, T., Nishino, N., Takada, A. and Nakamura, S. Larger and more invasive colo-rectal cancer contained larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlated well with tumor size. Cancer 86(12), 2602-2611, 1999
9. Sakata, K., Shirotani, M., Yoshida, H., Urano, T., Takada, Y. and Takada, A. Differential effects of analapril and nitrendipine on the fibrinolytic system in essential hypertension. Am. Heart J. 137 (6), 1094-1099, 1999
10. Endo A, Hashimoto K, Takada Y, Takada A.　The activation of the tissue plasminogen activator-plasmin system induced in the mouse hippocampus after injection of trimethyltin: Poosible proteolysis of highly polysialated NCAM.Jpn. J. Physiol. 49(5): 463-466 , 1999
11. Endo, A., Nagai, N., Urano, T., Takada, Y., Hashimoto, K. and Takada, Y. Proteolysis of neuronal cell adhesion molecule by the tissue plasminogen activator-plasmin system after kainate injection in the mouse hippocampus.Neuroscience Research 33, 1-8, 1999
12. Nagai, N., Urano, T., Endo, A., Takahashi, H., Takada, Y. and Takada, A. Neuronal degeneration and a decrease in laminin-like immunoreactivity is associated with elevated tissue-type plasminogen activator in the rat hippocampus after kainic acid injection.Neuroscience Research 33, 147-154, 1999
13. Takahashi, H., Urano, T., Nagai, N., Takada, Y. and Takada, A. Progressive expansion of hypertensive intracerebral hemorrhage by coagulopathy.Am. J. Hematology 59, 110-114, 1998
14. Takahashi, H., Urano, T., Nagai, N., Takada, Y. and Takada, A. Hyperfibrinolytic Activity After Head Injury Is Induced By Elevated tPA Activity. Fibrinolysis and Proteolysis 12(2), 113-118, 1998
15. Urano, T., Nagai, N., Matsuura, M., Ihara, H., Takada Y. and Takada, A. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity. Thromb Haemost 80, 161-166, 1998
16. Morita, S., Sato, A., Hayakawa, H., Ihara, H., Urano, T., Takada, Y. and Takada A. Cancer Cells Overexpress mRNA of Urokinase-Type Plasminogen Activator, Its Receptor And Inhibitors In Human Non-Small-Cell Lung Cancer Tissue: Analysis By Northern Blotting And In Situ Hybridization. Int J Cancer 78, 286-292, 1998
17. Takada, Y., Urano, T., Takahashi, H., Nagai, N. and Takada, A. Effects of electric footshock and water immersion restraint stresses on fibrinolytic parameters in the plasma of rats. Thromb. Res. 89, 107-114, 1998.
18. Nagai, N., Urano, T., Takada, Y. and Takada, A. Reperfusion after venous occlusion caused transient increase in plasminogen activator inhibitor-1 in systemic circulation.Clinical and Applied Thrombosis/Hemostasis, 4(2), 133-137, 1998
19. Takahashi, H., Urano, T., Takada, Y., Nagai, N. and Takada. Fibrinolytic parameters as an admission prognostic marker of head injury in patients who talk and deteriorate. J. Neurosurgery 86, 768-772, 1997
20. Imokawa, S., Sato, A., Hayakawa, H., Kotani, M., Urano, T., Takada, A. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. American Journal of Respiratory & Critical Care Medicine, 156(2 Pt1):631-6, 1997
21. Rydzewski, A., Urano, T., Nagai, N., Takada, Y., Katoh-Oishi, Y., Taminato, T., Yoshimi, T. and Takada, A. Diurnal variation in serum remnant-loke lipoproteins, platelet aggregation and fibrinolysis in healthy volunteers.Haemostasis, 27, 305-314, 1997
22. Urano, T., Nishikawa, T., Nagai, N., Takada, Y. and Takada, A. Amounts of tPA and PAI-1 in the euglobulin fraction obtained at different pH: Their relation to the euglobulin clot lysis time. Thromb. Res. 88(1), 75-80, 1997
23. Urano T., Ihara H., Takada Y., Nagai N. and Takada A. The inhibition of human factor Xa by plasminogen activator inhibitor type 1 in the presence of calcium ion, and its enhancement by heparin and vitronectin. Biochim. Biophys. Acta 1298, 199-208, 1996
24. Mochizuki M., Takada Y., Urano T., Nagai N., Nakano T., Nakajima K. and Takada A. The in vitro effects of chylomicron remnant and very low density lipoprotein remnant on platelet aggregation in blood obtained from healthy persons. Thromb Res. 81(5), 583-593, 1996
25. Malyszko J., Urano T., Knofler R., Takada Y. and Takada A. Effects of short term treatment with mevalotin on platelet aggregation, fibrinolysis, peripheral serotonergic system and serum lipids in Japanese monkeys.Thromb. Res. 81(2), 397-402, 1996
26. Wu, K., Urano, T., Ihara, H., Takada, Y., Fujie, M., Shikimori, M., Hashimoto, K. and Takada, A. The Cleavage and Inactivation of Plasminogen Activator Inhibitor Type 1 by Neutrophil Elastase: The Evaluation of Its Physiological Relevance in Fibrinolysis. Blood 86, 1056-1061, 1995
27. Urano, T., Serizawa, K., Takada, Y., Ny, T. and Takada, A.Heparin and heparan sulphate enhancement of the inhibitory activity of plasminogen activator inhibitor type 1 toward urokinase type plasminogen activator.Biochim. Byophys. Acta 1201, 217-222, 1994
28. Kojima, Y., Urano, T., Kojima, K., Serizawa, K., Takada, Y. and Takada, A.The Significant Enhancement of Fibrinolysis by Calcium Ion in a Cell Free System. : The Shortening of Euglobulin Clot Lysis Time by Calcium Ion.Thromb. Haemostas.72(1), 113-118, 1994
29. Takada, Y., Urano, T. and Takada, A.Effect of heparan sulfate analogue or other sulfated polysaccharides on the activation of plasminogen by t-PA or u-PA.Thromb. Res.73(5), 301-311, 1994
30. Nagayama, M., Sato, A., Hayakawa, H., Urano, T., Takada, Y. and Takada, A. Plasminogen activators and their inhibitors in non-small cell lung cancer: Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 73(5), 1398-1405, 1994
31. Aoki, K., Nishino, N., Baba, S., Urano, T. and Takada, A. Postoperative changes in plasma tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. Surg Today Jpn J Surg 24, 1039-1043, 1994
32. Malyszko, J., Urano, T., Knofler, R., Ihara, H., Shimoyama, I., Uemura, K., Takada, Y. and Takada, A. Correlation between platelet aggregation, fibrinolysis, peripheral and central serotonergic measures in subhuman primates.Atherosclerosis 110, 63-68, 1994
33. Malyszko, J., Urano, T., Knofler, R., Ihara, H., Takada, Y. and Takada, A. Relationships between serum lipids, serotonin, platelet aggregation and some fibrinolytic parameters in humans. Life Sciences 55(21), 1619-1623, 1994
34. Malyszko, J., Urano, T., Knofler, R., Taminato, A., Yoshimi, T., Takada, Y. and Talkada, A. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb. Res. 75(5), 569-576, 1994
35. Malyszko, J., Urano, T., Takada, Y. and Takada, A. Stress dependent changes in fibrinolysis, serotonin and platelet aggregation in rats.Life Sci. 54(17): 1275-1280, 1994
36. Malyszko, J., Urano, T., Takada, Y. and Takada, A. Time-dependent changes in platelet aggregation, fibrinolytic activity, and peripheral serotnergic measures in rats subjected to water-immersion restraint stress. Haemostasis 24, 236-242, 1994
37. Urano T., Malyszko J., Serizawa K., Kozima Y., Takada Y. and Takada A. Electric-foot-shock induced the supression of fibrinolytic activity in rats. Thromb. Res. 74(6): 595-603, 1994
38. Takada, Y., Urano, T. and Takada, A.Conformational change of plasminogen: Effects of N-terminal peptides of Glu-plasminogen.Thromb. Res.70; 151-159, 1993
39. Takada, Y., Urano, T., Watanabe, I., Taminato, A., Yoshimi, T., Takada, A. Changes in fibrinolytic parameters in male patients with type 2 (non insulin dependent) diabetes mellitus. Thromb. Res. 71, 405-415, 1993.
40. Urano, T., Kojima, Y., Takahashi, M., Serizawa, K., Sakakibara, K., Takada, Y. and Takada, A. Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma. Jpn. J. Physiol. 43, 221-228, 1993
41. Urano T., Strandberg L., Johansson L. B-A., Ny T.A substrate-like form of plasminogen activator inhibitor type 1: Conversions between different forms by sodium dodecyl sulphate.Eur. J. Biochem.209, 985-992, 1992
42. Sumiyoshi, K. Serizawa, T. Urano, Y. Takada, A. Takada and S. Baba. Plasminogen activator system in human breast cancer. Int. J. Cancer 50, 345-348, 1992.
43. Nakamura, M., Konnno, H., Tanaka, T., Maruo, Y., Nishino, N., Aoki, K., Baba, S., Sakaguchi, S., Takada, Y. and Takada, A. Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. Thromb. Res. 65: 709-719, 1992
44. Sakata, K., Hoshino, T., Yoshida, H., Ono, N., Ohtani, S., Yokoyama, S., Mori, N., Kaburagi, T., Kurata, C., Urano, T., Takada, Y. and Takada, A. Circadian fluctuations of tissue plasminogen activator antigen and plasminogen activator inhibitor-1 antigens in vasospastic angina. Am. Heart J. 124(4): 854-860, 1992
45. Kawamura, I. Watanabe, T. Urano, Y. Takada and A. Takada.The effects of polysaccharides on plasminogen activation by single chain-tissue plasminogen activator.Thromb. Res.62, 481-490, 1991
46. T. Urano, Y. Takada and A. Takada.Stimulation of the amidolytic activity of single chain tissue-type of plasminogen activator by fibrinogen degradation products : possible binding sites on single chain tissue plasminogen activator molecule.Biochim. Biophys. Acta 1077; 245-252, 1991.
47. Urano, T. Sumiyoshi, K. Pietraszek, M. H. Takada, Y. and Takada, A. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA.Thrombos. Haemostas. 66(4) 474-478, 1991
48. Sumiyoshi, S. Baba, S. Sakaguchi, T. Urano, Y. Takada and A. Takada. Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis. Thromb. Res. 63, 59-71, 1991
49. Urano T., Sakakibara K., Rydzewski A., Urano S., Takada Y. and Takada A. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator inhibitor 1. Thrombos. Haemostas. 63; 82-86, 1990
50. Urano, T., de Serrano, V. S., Urano, S. and Castellino, F. J.Stimulation by fibrinogen of the amidolytic activity of single-chain tissue plasminogen activator.Arch Biochem. Biophys.270(1): 356-362, 1989
51. Urano, T., de Serrano, V. S. Gaffney, P. J. and Castellino F. J.Effectors of the activation of human [Glu1] plasminogen by human tissue plasminogen activator.Biochemistry 27:6522-6528, 1988.
52. Urano, T., de Serrano, V. S., Chibber, B. A. K. and Castellino, F. J.The control of the urokinase-catalyzed activation of human glutamic acid 1-plasminogen by positive and negative effectors.J. Biol. Chem.262(33): 15959-15964, 1987.
53. Urano, T., Chibber, B. A. K. and Castellino, F. J.The reciprocal effects of e-aminohexanoic acid and chloride ion on the activation of human (Glu1) plasminogen by human urokinase.Proc. Natl. Acad. Sci. USA84: 4031-4034, 1987.
54. Urano, T., Kamiya, T., Sakaguchi, S., Takada, Y. and Takada, A. Fibrinogenolysis and fibrinolysis in normal volunteers and patients with thrombosis after infusion of urokinase. Thromb. Res. 39(2): 145-155, 1985.
55. Urano, T. Takada, Y. and Takada, A. The enhanced activation of Glu- and Lys-plasminogen by urokinase in the presence of fibrin or Des A Fibrin as measured by the release of Ba peptide and FDP. Thromb. Res. 36(5): 429-435, 1984.
56. Takada A. and Takada Y. Effects of w-aminoacids and clot formation on the activation by urokinase of various plasminogen preparations.Thromb. Res. 18(1/2): 167-176, 1980
57. Takada, A., Urano, T. and Takada, Y. Influence of coagulation on the activation of plasminogen by streptokinase and urokinase.Thrombos. Haemostas. 42(3): 901-908, 1979
58. Takada A. and Takada Y. Studies on SK-potentiator of plasminogen in human plasma. Thrombos. Res. 13(2): 325-335, 1978

総 説

2012

1. Iwaki T, Urana T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 157(3), 291-8, 2012
2. Urano T, Suzuki Y. Accelated fibriolysis and its propagation on vascular endothelial cells by secreted and retained tPA. J Biomed Biotechnol 2012, 208108, 2012

2011

1. Suzuki Y, Urano T. Novel situations of endothelial injury in stroke: mechanisms of stroke and strategy of drug development: novel mechanism of the expression and amplification of cell surface-associated fibrinolytic activity demonstrated by real-time imaging analysis. J Pharmacol Sci 116(1), 19-24, 2011
2. 浦野哲盟、鈴木優子　線溶系検査の意味するところ　 臨床病理 59(7) , 703-708, 2011
3. 浦野哲盟　血栓形成の分子機構：凝固に伴い線溶活性が増強する機構　Thrombosis Medicine 1(1), 89-92, 2011
4. 浦野哲盟　血栓形成の分子機構：組織因子の構造変化と強固活性発現調節　Thrombosis Medicine 1(1), 89-92, 2011
5. 浦野哲盟　線溶機序　脈管学51(3), 293-299, 2011
6. 鈴木優子　血管内皮細胞表面における滞留tPA惹起線溶活性増幅機構のイメージング解析　血栓止血学会誌22, 374-376, 2011
7. 鈴木優子　血管内皮細胞上の線溶活性調節機構　血液フロンティア21, 1571-1579, 2011

2009

1. 浦野哲盟　線溶療法の考え方と治療薬剤　日本血栓止血学会誌20(4), 398-400, 2009
2. 井原勇人　脂肪細胞から分泌される生理活性物質アディポカイン遺伝子発現制御　比較生理生化学26(2), 47-57, 2009
3. Suzuki Y, Urano T. Secretory dynamics of tPA and its modulation by PAI-1 in vascular system. Rinsyo Ketsueki, 50(5), 399-403, 2009
4. 鈴木優子　血管内皮細胞におけるtPAの独特な分泌形態とPAI-1による修飾　日本血栓止血学会誌20, 428-436, 2009
5. 井原隼人　機能性食品成分によるメタボリック症候群発症に関わるアディポカイン遺伝子発現抑制機構の解析：赤ワインに含まれるレスベラトールの効果を中心として　フードリサーチ（特集号　メタボ対策とアンチエイジング）645, 22-25,2009

2008

1. 浦野哲盟、鈴木優子、井原隼人、最上秀夫　血液及び血管内皮から見た血栓症リスク　日本血栓止血学会誌19(4), 491-494, 2008
2. 浦野哲盟、鈴木優子、林忠毅、最上秀夫　生体内リアルタイムイメージングによる血栓形成過程の解析　日本血栓止血学会誌19(6), 808-813, 2008
3. 浦野哲盟、鈴木優子、井原隼人、最上秀夫　血液および血管内皮から見た血栓症リスク　日本病態生理学会雑誌17(1), 34-36, 2008

2007

1. 浦野哲盟　侵襲時の線溶活性＝病態増悪因子としての plasminogen activator inhibitor type 1 (PAI-1) とプロテアーゼインヒビター　Surgery Frontier 14(1), 109-113, 2007　
2. 鈴木優子、浦野哲盟　血漿 tPA 及び PAI-1 抗原量測定の意義　ー新たな知見からの再考察ー　日本血栓止血学会雑誌、18(3), 247-254, 2007　
3. 浦野哲盟　抗炎症療法と血管病予防の関連を探る　Vascular Medicine 3(4), 333-338, 2007
4. 浦野哲盟　侵襲時の線溶活性：病態増悪因子としての plasminogen activator inhibitor type 1 (PAI-1) とプロテアーゼインヒビター　Surgery Frontier 14(1), 109-113, 2007

2006

1. 浦野哲盟　アスピリンの心筋梗塞発症予防のメカニズム　３アスピリンの抗炎症作用と心筋梗塞発症予防　治療学40(3), 273-277, 2006
2. 浦野哲盟　線溶療法　日本血栓止血学会誌17(6), 676-681, 2006
3. 浦野哲盟　データ解説（脳梗塞の tPA 静脈内投与）　International Review of Thrombosis 4(1), 66-67, 2006
4. 浦野哲盟　アスピリンの抗炎症作用と心筋梗塞発症予防　治療学 40(3), 273-277, 2006

2005

1. 鈴木優子、浦野哲盟　tPA と vascular biology　血管医学Vol 6 (3), 269-277, 2005
2. 鈴木優子、浦野哲盟　血管内皮細胞による血栓形成・線溶の調節の基礎　分子血管病Vol 6 (1), 13-18, 2005

著 書

1. 浦野哲盟　凝固・線溶系からみた病態　動脈硬化：血栓症疾患ハンドブック 21-30, 2009
2. 浦野哲盟　線溶系　講義録：血液・造血器疾患学 36-37, 2008
3. Nagai N and Urano T. Role of tPA in the neural system. In Recent Advances in Thrombosis and Hemostasis. Edited by K. Tanaka and E.W. Davie. Springer, Tokyo pp. 314-327, 2008
4. 浦野哲盟　抗血小板効果以外のアスピリンによる心血管発症予防メカニズム　臨床現場におけるアスピリン使用の実際118-124, 2006
5. 最上秀夫　高速度冷却 CCD カメラとイメージインテンシファイアー　染色・バイオイメージング実験ハンドブック。細胞や組織の形態・遺伝子・タンパク質を観るための染色法と蛍光顕微鏡のすべ　実験医学別冊268-274, 2006
6. 浦野哲盟　血液、造血器、リンパ系　人体生理学, 2006
7. 浦野哲盟　t-PA, t-PA/PAI-1 複合体, PAI-1　検査値のみかた, 2006
8. 浦野哲盟　プラスミノーゲン、α２プラスミンインヒビター、α２PI プラスミン複合体　検査値のみかた, 2006
9. 浦野哲盟　FDP, D ダイマー　検査値のみかた, 2006
10. 浦野哲盟　プラスミノーゲン　血液の事典, 318-320, 2005
11. 井原 勇人、浦野 哲盟　プラスミノーゲン・アクチベーター・インヒビター1の基礎と臨床　図説　血栓、止血、血管学606-613, 2005
12. 浦野哲盟　tPA の基礎と臨床　図説　血栓、止血、血管学, 549-553, 2005